AC
IKT icon

Antara Capital’s Inhibikase Therapeutics IKT Stock Holding History

Antara Capital’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-67,167
Closed -$299K – 214
2022
Q2 		$299K Buy
67,167
+16,667
+33% +$98.3K 0.01% 169
2022
Q1 		$448K Hold
50,500
– – 0.01% 180
2021
Q4 		$445K Hold
50,500
– – 0.02% 153
2021
Q3 		$576K Buy
50,500
+8,833
+21% +$119K 0.04% 123
2021
Q2 		$700K Buy
+41,667
New +$1.23M 0.04% 130

Other funds holding IKT

ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.88B AUM 29.07% 1-Year Est. Return

Antara Capital's IKT Position: Q3 2022 in Review

Antara Capital sold out of Inhibikase Therapeutics (IKT) in Q3 2022, closing a stake of 67,167 shares — an estimated $299K sold.

Antara Capital first reported a position in IKT in Q2 2021 and held it in 5 quarters. The position peaked at $700K in Q2 2021. 24 funds tracked by Wall St. Rank hold IKT as of Q3 2022.

  • Antara Capital reported no remaining Inhibikase Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Antara Capital sold 67,167 Inhibikase Therapeutics shares in Q3 2022, an estimated $299K.
  • Antara Capital first reported a position in Inhibikase Therapeutics in Q2 2021 and held it in 5 quarters.
  • Antara Capital's Inhibikase Therapeutics position peaked at $700K in Q2 2021.
  • 24 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2022.

Based on Antara Capital's 13F filing for Q3 2022, filed 14 Nov 2022.